GlobeNewswire Inc.·6h ago·NaLexicon Advances Pain Drug After Positive Phase 2b ResultsLexicon Pharmaceuticals' pilavapadin shows promise in diabetic neuropathic pain study, supporting 10mg dose selection for Phase 3 trials. LXRXclinical trialPhase 3
GlobeNewswire Inc.··Na